drugset / Trial / NCT06149611

Mass Balance Study of TQB3616

NCT06149611

NaSingle-groupOpen-labelTreatment

Summary

This is a clinical study exploring the mass balance of \[14C\] TQB3616 in healthy Chinese subjects aims to quantitatively analyze the total radioactivity in the feces of male healthy subjects after oral administration of \[14C\] TQB3616, obtain data on human radiation excretion rate and main excretion pathways, investigate the distribution in whole blood and plasma, plasma distribution, and pharmacokinetics of total radioactivity in plasma, identify main metabolites, and determine the main biological transformation pathways, obtain the pharmacokinetic parameters of TQB3616 and its metabolites in plasma. The primary endpoint is mass balance, radiopharmacokinetics, plasma pharmacokinetics, and metabolites.

Timeline

Start
2024-01
Primary completion
2024-06
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject TQB3616 Small molecule 180 mg Oral

Indications